Rocket One Inc.

Listed Company

HOTHCIK 0001711786NasdaqEmerging GrowthPharmaceutical PreparationsNevadaFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-12.47M

Total Assets

$7.60M

Equity

$6.15M

Shares Out

16.26M

Op. Cash Flow

$-9.80M

Business

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for unmet medical needs. Its main products in development include HT-001 (topical for EGFR inhibitor‑induced skin toxicities), HT-KIT (KIT‑targeting therapy for mast cell cancers and anaphylaxis), HT-ALZ (repurposed agent for Alzheimer’s/neuroinflammation), BioLexa (topical zinc chelator plus antibiotic for atopic dermatitis), HT-004 (inhaled exon‑skipping oligonucleotide for asthma/allergy) and HT-VA (GDNF‑based obesity therapy). Key business segments consist of program-specific development pipelines and the BioLexa platform, supported by academic licenses and sponsored research. The company pursues global development and regulatory interactions (notably U.S. FDA pathways), relies on contract manufacturers and CROs, and plans third‑party commercialization and licensing for distribution.

Summary from filing dated 2025-03-28

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
NET REVENUES	—	—	—	—	—
Research and development expenses	6	3	4	5	7
General and administrative expenses	6	5	4	6	—
Total operating expenses	12	8	8	11	14
LOSS FROM OPERATIONS	−12	−8	−8	−11	−14
Change in fair value of investment in joint venture	—	−581	4,400	—	—
Unrealized loss on crypto assets	−108,633	—	—	—	—
Dividend and interest income	680	27,713	51,772	—	—
Total other (expenses) income, net	−107,953	27,132	−153,148	−306,399	−212,265
NET LOSS	−12	−8	−8	−11	−14
Basic (per share)	−0.9	−1.28	−2.38	−9.5	−16.02
Diluted (per share)	−0.9	−1.28	−2.38	−9.5	−16.02
Basic (shares)	14	6	3	1	893,226
Diluted (shares)	14	6	3	1	893,226
Foreign currency translation adjustment	1,768	−18,197	5,254	4,420	32,937
Total comprehensive loss	−12	−8	−8	−11	−14

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2024 2024-09-30	FY 2024 2024-06-30	FY 2024 2024-03-31
Cash and cash equivalents	6	7	—	—	—
Prepaid expenses and other current assets	366,548	605,948	656,386	839,037	910,179
Crypto assets, at fair value	191,367	—	—	—	—
Deferred offering costs	57,171	—	—	—	—
Total Current Assets	7	8	9	10	9
Prepaid expenses and other assets, net of current portion	699,420	—	—	—	—
Operating lease right-of-use asset, net	4,652	31,075	—	—	—
Investment in joint ventures at fair value	36,819	36,819	—	—	—
Total Non-Current Assets	740,891	67,894	—	—	—
Total Assets	8	8	9	11	9
Accounts payable	823,674	412,071	—	—	—
Accrued expenses	623,323	390,760	—	—	—
Operating lease liability, current portion	5,678	28,366	—	—	—
Total Current Liabilities	1	831,197	—	—	—
Operating lease liability, less current portion	—	2,709	—	—	—
Total Long-Term Liabilities	—	2,709	—	—	—
Total Liabilities	1	833,906	—	—	—
Commitments and Contingencies (Note 6)	—	—	—	—	—
Preferred stock, $0.0001 par value, 10,000,000 shares authorized; 3,000,000 shares undesignated; 0 shares issued and outstanding as of December 31, 2025 and 2024	—	—	—	—	—
Common stock, $0.0001 par value; 50,000,000 shares authorized; 15,514,312 and 8,042,747 shares issued and outstanding as of December 31, 2025 and 2024, respectively	1,551	850,500	—	—	—
Additional paid-in capital	79	67	—	—	—
Accumulated deficit	−73	−60	−58	−56	−54
Accumulated other comprehensive income	10,831	9,063	—	—	—
Total Stockholders Equity	6	7	8	10	8
Total Liabilities and Stockholders Equity	8	8	9	11	9

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development-acquired patent, expensed	850,500	—	−275,000	—	—
Stock-based compensation	1	804,277	216,428	620,798	1
Stock-based professional fees	333,150	—	—	—	—
Lease costs	1,026	—	—	—	—
Unrealized loss of crypto assets	108,633	—	—	—	—
Prepaid expenses and other current assets	−460,020	252,178	213,432	3,847	−5,420
Accounts payable and accrued expenses	644,166	153,013	−700,752	—	—
NET CASH USED IN OPERATING ACTIVITIES	−10	−7	−8	−9	−12
Purchase of crypto assets	−300,000	—	—	—	—
NET CASH USED IN INVESTING ACTIVITIES	−300,000	—	—	1	−165,355
Proceeds from issuance common stock, net of offering costs	4	—	11	6	4
Proceeds from issuance of common stock, common stock warrants and prefunded warrants, net of offering costs	—	1	—	—	—
Proceeds from exercise of warrants	6	4	2,355	—	359,513
Taxes paid related to net share settlement of equity award	−376,000	—	—	—	—
Payment of deferred offering costs	−57,171	—	—	—	—
NET CASH PROVIDED BY FINANCING ACTIVITIES	9	5	11	6	18
NET DECREASE IN CASH AND CASH EQUIVALENTS	−793,224	−2	3	−2	—
Effect of exchange rate changes on cash and cash equivalents	1,768	−18,197	−6,518	−9,593	−30,562
Increase in prepaid expenses and other current assets and additional paid-in capital related to issuance of warrants for future services	333,150	—	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro